Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model
复制标题
DOI：
10.1016/j.canlet.2008.09.026
复制
发表时间：
2009-02-18
期刊：
影响因子：
9.7
通讯作者：
Kubo, Toshikazu
中科院分区：
文献类型：
--
作者：
Koto, Kazutaka;Horie, Naoyuki;Kubo, Toshikazu
临床可获得的唑来膦酸（ZOL）浓度抑制血管内皮生长因子的产生，并减少骨肉瘤（OS）细胞在体外的迁移，粘附和侵袭。通过使用自发性肺转移的小鼠模型研究ZOL的体内作用。较高剂量的ZOL（80 μ g/kg，每周三次）抑制了原发部位OS的生长，同时抑制了肿瘤中的新血管形成。有趣的是，虽然较低剂量的ZOL（80 μ g/kg，每周一次）不能抑制CS在原发部位的生长，但它显著防止了肺转移。(C)2008爱思唯尔爱尔兰有限公司保留所有权利。
Clinically obtainable concentrations of zoledronic acid (ZOL) inhibited the production of vascular endothelial growth factor and reduced the migration, adhesion, and invasiveness of osteosarcoma (OS) cells in vitro. The in vivo effects of ZOL were investigated by using a murine model of spontaneous lung metastasis. The higher dose of ZOL (80 mu g/kg three times/week) inhibited the growth of OS at the primary site, accompanied by inhibition of neovascularization in the tumor. Interestingly, while the lower dose of ZOL (80 mu g/kg once a week) could not inhibit the growth of CS at the primary site, it significantly prevented lung metastasis. (C) 2008 Elsevier Ireland Ltd. All rights reserved.